Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.
Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...
Singer Linda Nolan was brought to her funeral in a pink sparkly coffin as a large crowd of family and friends gathered in ...
Great Diamond Partners LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.2% during the ...
Mediolanum International Funds Ltd decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 67.7% ...
Nolan married her husband of more than two decades, Brian Hudson, in the Blackpool church, and said goodbye to him there ...
Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback